# Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

> **NCT07185841** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fujian Haixi Pharmaceuticals Co., Ltd.** · enrollment: 198 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** HX9428 tablet

## Key facts

- **NCT ID:** NCT07185841
- **Lead sponsor:** Fujian Haixi Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-01-07
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185841, "Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07185841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*